Ascendia

  MARKET NEWS

FDA Approves the Manufacture of New Microbiome-Based Therapeutic at Recipharm Site
Veranova Appoints New Chief Executive Officer
Omnix Medical Announces Excellent Topline Data From Phase 1 Clinical Trial of Novel Anti-Infective
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration With GSK
Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy
Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201

  FEATURED EDITORIAL

  COMPANY PROFILE

Lonza CHI is a preferred global partner to the pharmaceutical, biotech and nutraceutical markets. ​Our pioneering Capsugel capsules and encapsulation technologies help improve speed of development and execution and the match of dosage form performance to ingredients or API application. Our product portfolio and product services for pharmaceutical partners include: Capsules including customizations, Equipment, and Ingredient/API formulation services. Click here for more.

  EXCLUSIVE ONLINE CONTENT

 

Eisai Enters Joint Development Agreement With Blissbio for Antibody Drug Conjugate With Option Rights for Strategic Collaboration

Eisai Enters Joint Development Agreement With Blissbio for Antibody Drug Conjugate With Option Rights for Strategic Collaboration

Eisai Co., Ltd. recently announced it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd., for BB-1701, an antibody-drug conjugate (ADC) with option rights for a….

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra to Prevent Cytokine Release Syndrome Resulting From CAR T-Cell Therapy

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra to Prevent Cytokine Release Syndrome Resulting From CAR T-Cell Therapy

Enlivex Therapeutics Ltd. recently announced the issuance of a European patent, No. 3865189, titled Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment. The patent provides added intellectual….

Arranta Bio Signs Contract With MIT to Develop Rapid Manufacturing of mRNA Therapeutics

Arranta Bio Signs Contract With MIT to Develop Rapid Manufacturing of mRNA Therapeutics

Arranta Bio, part of Recipharm’s biologics business, has recently signed a contract with MIT to develop a continuous manufacturing technology for mRNA therapeutics. The contract is part….

Hovione & H&T Presspart Extend Partnership to Advance High-Efficiency Device Technology for Dry Powder Inhalation Formulation Delivery

Hovione & H&T Presspart Extend Partnership to Advance High-Efficiency Device Technology for Dry Powder Inhalation Formulation Delivery

Hovione and H&T Presspart have entered in a strategic partnership to advance the development of Presspart’s Sunriser Capsule-based Dry Powder Inhaler platform. The demand for….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

The effectiveness of inhalation devices relies on their ability to deliver the pharmaceutical directly to the targeted part of the body with precision and calculated dosing.  Since these devices….

  WHITEPAPERS & WEBINARS

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

Aseptic processing with the highest degree of sterility assurance, filling accuracy, and quality is critical for high-value, small-batch therapies. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing.

CLICK HERE TO DOWNLOAD/VIEW THE …

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

 

Synchronizing and controlling API delivery, extrusion-spheronization (E-S) offers pharmaceutical companies a robust technique to manufacture today’s most complex therapeutics. Manufacturing oral solid dose (OSD) APIs into spheres via E-S is not new. What is new is that in the …

WHITEPAPER - Unique Manufacturing Challenges Associated With Sterile Eye Ointments

WHITEPAPER - Unique Manufacturing Challenges Associated With Sterile Eye Ointments

The manufacture of ophthalmic ointments is much more complex than the production of ocular liquid therapies and presents several unique challenges. It is essential for drug developers to choose outsourcing partners with extensive manufacturing experience with these specialized capabilities in …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 17 – Injection Devices
May 24 – Parenteral Contract Manufacturing